Abstract 1064P
Background
Due to increasing incidence of cancer and shortage of hospital resources there is a need for a more time-efficient work process at the hospital-daycare-unit. A large proportion of our patients are treated with monoclonal antibodies. These drugs are administered according to the infusion times stated in the drug label. In this pilot study we investigated if it is safe to reduce total infusion time for nivolumab, ipilimumab or pembrolizumab.
Methods
We included patients who received nivolumab every 3 or 4 weeks (320-480mg), ipilimumab (1 or 3 mg/kg) every 3 or 6 weeks and nivolumab (1 or 3 mg/kg) every 3 weeks or pembrolizumab (100-400mg) every 3-6 weeks. The patients had to receive ≥2 administrations without a previous infusion related reaction (IRR) grade ≥2 before they entered the intervention phase where the infusion time was reduced to respectively 15 and 10 minutes. IRRs were graded according to CTCAE v5.0 and the incidence was calculated. Secondly, patient-reported experience measures (PREM) were collected before and after shorted infusion times.
Results
In total 60 patients, 20 per cohort were included. In the nivolumab cohort one IRR grade 2 occurred during the second standard of care 30-minute infusion, and two IRRs occurred during the 15-minute infusion (one grade 1, and one grade 2). No IRRs occurred during the 10-minute infusions. In the ipilimumab/nivolumab cohort one IRR grade 2 occurred during the second standard of care 30-minute infusion of nivolumab, and one IRR grade 1 during the 10-minute infusion of nivolumab. No IRRs occurred during the infusions of ipilimumab. In the pembrolizumab cohort only one grade 1 IRR occurred during the 10-minute infusion. In all cohorts there was no IRR grade 3 or higher. Of the patients who received shorter infusion times 95% were (very) satisfied. A total of 3045 minutes were saved during the intervention phase.
Conclusions
Shorter infusion times up to 10 minutes for nivolumab, ipilimumab/nivolumab and pembrolizumab were applied without a clinical relevant increase of IRRs. Besides increasing time-efficiency, patients were very satisfied with the reduced infusion times. In conclusion, this strategy for optimizing infusion rates of monoclonal antibodies seems to be safe and for further exploration.
Clinical trial identification
NCT06031233.
Editorial acknowledgement
Legal entity responsible for the study
Isala Hospital.
Funding
Partly funded by BMS and Research Foundation Isala Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1132P - Regorafenib in Caucasian patients with pretreated advanced KIT-mutant melanoma: A dual center case series
Presenter: Iris Dirven
Session: Poster session 04
1133P - Only early adjuvant radiotherapy, particularly of the tumor bed rather than the lymph node region, improves prognosis in Merkel cell carcinoma: Results from the prospective German MCC registry
Presenter: Juergen Becker
Session: Poster session 04
1134P - Avelumab in metastatic Merkel cell carcinoma (mMCC): Conditional survival and long-term safety in patients treated for ≥1 or ≥2 years in JAVELIN Merkel 200
Presenter: Celeste Lebbe
Session: Poster session 04
1135P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment of Merkel cell carcinoma
Presenter: Maximilian Haist
Session: Poster session 04
1136P - Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study
Presenter: Eva Muñoz-Couselo
Session: Poster session 04
1137P - Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors
Presenter: Justine Cohen
Session: Poster session 04
1138P - A prospective study of patients with immune checkpoint inhibitor-induced hepatitis: Management outcome and association with liver injury subtype, immune infiltration, and clinical parameters
Presenter: Rikke Holmstroem
Session: Poster session 04
1139TiP - IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma
Presenter: Marcus Butler
Session: Poster session 04
1140TiP - Safe stop IPI-NIVO trial: Early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab
Presenter: Joséphine Janssen
Session: Poster session 04
1210P - Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study
Presenter: Marina Garassino
Session: Poster session 04